Ciamexon

SKU: orb1819186

Description

Ciamexon (Ciamexone) is a low-cytotoxicity immunomodulator studied in autoimmune disease models. Research applications include investigating its effects in experimental endocrine ophthalmopathy and diabetes mellitus, where short-term in vivo administration has shown modest benefits.

Key Properties

• CAS Number: 75985-31-8
• MW: 203.24
• Purity: >99.99% (May vary between batches)
• Formula: C₁₁H₁₃N₃O
• SMILES: C(N1C(C#N)C1)C2=C(OC)N=C(C)C=C2
• Target: Others
• Solubility: DMSO:55 mg/mL (270.62 mM)

Bioactivity

• In Vivo:
  Ciamexon on the development of diabetes in BB rats. Ciamexon was given once daily for 6 days per week beginning with the age of 42 or 50 days up to 120 days. For comparison, cyclosporin A (10 mg/kg) was applied following the same protocol. At 1 mg/kg, Ciamexon administration led to the complete prevention of diabetes in females but was not beneficial in males. At 10 mg/kg the drug caused significant suppression of diabetes development in males but more pronounced in females. Both, a reduction in the incidence of diabetes and a delay in the onset of hyperglycemia was observed only in females. After administration of cyclosporin A none of the animals developed diabetes. Ciamexon treatment did not affect granulocyte and lymphocyte counts and subsets in the peripheral blood except for a tendency to suppress eosinophilia. The growth of animals was not retarded. It is concluded that Ciamexon seems to influence the autoimmune state of the BB rat resulting in partial suppression of the disease.
  Read more...

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

BM 41332, BM41332, BM-41332, Ciamexon, Ciamexone

Compound Identifiers

PubChem CID

71759